IDEAS home Printed from https://ideas.repec.org/h/spr/sprchp/978-981-97-1471-1_5.html
   My bibliography  Save this book chapter

The Art of the Biopharma Deal: The China Angle

In: Biopharma in China

Author

Listed:
  • Sven Agten
  • Ben Wu

Abstract

Over the last years foreign companies have been very active in partnership and cooperation deals with Chinese biopharma companies and healthcare investors. Anybody who wants to raise money from Chinese investors or strike a partnering or cooperation deal with Chinese companies however, needs to understand what investors or Chinese pharma companies are looking for. And because of the vast differences and needs of the Chinese healthcare and pharmaceutical market, the value proposition towards China can be very different than other markets. The most reputable and well-known USD-denominated healthcare funds in China are originally from the US, but have very specific funds to invest in China or ex-US. Then there are the strategic investors who are actively investing in, and in-licensing assets from foreign companies. There are mainly two categories of strategic investors: the newly established, venture capital backed biopharma companies, and the traditional Chinese pharmaceutical companies. It’s important to understand the background of these companies. The traditional pharma companies are not rooted in innovation, and as such are not always that familiar with the process of drug discovery. The newly established biopharma companies on the other hand are well versed in innovation, but of course don’t have the established sales network as the big pharma companies. Just like the US or Europe, Chinese investors have also engaged in incubating or building new biopharma companies. As a matter of fact at the height of the biotech investment boom, almost all Chinese biotechs have been incubated by healthcare venture capitalists, and were not spun out from universities or research institutes, as is often the case in the US or Europe.. As such it’s important to understand that incubation or new venture building in China is fundamentally different than in Europe or the US. Lastly it’s important to understand what diseases are more prevalent in China, or which technologies are more needed than others.

Suggested Citation

  • Sven Agten & Ben Wu, 2024. "The Art of the Biopharma Deal: The China Angle," Springer Books, in: Biopharma in China, pages 101-112, Springer.
  • Handle: RePEc:spr:sprchp:978-981-97-1471-1_5
    DOI: 10.1007/978-981-97-1471-1_5
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:sprchp:978-981-97-1471-1_5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.